The NKG2A immune checkpoint — a new direction in cancer immunotherapy

被引：0
|
作者：
Benjamin C. Creelan
Scott J. Antonia
机构：
[1] H. Lee Moffitt Cancer Center & Research Institute,Thoracic Oncology Department
[2] Duke Cancer Institute,DCI Center for Cancer Immunology
来源：
Nature Reviews Clinical Oncology | 2019年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer. However, established biomarkers of response are lacking, and larger trials are needed to enable firm conclusions to be drawn about whether NKG2A inhibition complements existing immunotherapies.
引用
收藏
页码：277 / 278
页数：1
相关论文
共 50 条
  • [1] The NKG2A immune checkpoint - a new direction in cancer immunotherapy
    Creelan, Benjamin C.
    Antonia, Scott J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) : 277 - 278
  • [2] NKG2A, a New Kid on the Immune Checkpoint Block
    Haanen, John B.
    Cerundolo, Vincenzo
    [J]. CELL, 2018, 175 (07) : 1720 - 1722
  • [3] NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy
    Cazzetta, Valentina
    Depierreux, Delphine
    Colucci, Francesco
    Mikulak, Joanna
    Mavilio, Domenico
    [J]. CANCERS, 2023, 15 (04)
  • [4] Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy
    Beelen, Nicky A.
    Valckx, Vera T. C.
    Bos, Gerard M. J.
    Wieten, Lotte
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2024, 37 (03)
  • [5] Monalizumab: inhibiting the novel immune checkpoint NKG2A
    van Hall, Thorbald
    Andre, Pascale
    Horowitz, Amir
    Ruan, Dan Fu
    Borst, Linda
    Zerbib, Robert
    Narni-Mancinelli, Emilie
    van der Burg, Sjoerd H.
    Vivier, Eric
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [6] NKG2A and HLA-E define an additional immune checkpoint axis in bladder cancer
    Salome, Berengere
    Sfakianos, John P.
    Daza, Jorge
    Charap, Andrew
    Farkas, Adam M.
    Geanon, Daniel
    Kelly, Geoffrey
    De Real, Ronaldo M.
    Lee, Brian
    Beaumont, Kristin G.
    Shroff, Sanjana
    Wang, Ying Chih
    Wang, Yuan Shuo
    Wang, Li
    Sebra, Robert P.
    Romero, Pedro
    Brody, Rachel
    Carrington, Mary
    Wiklund, Peter
    Mehrazin, Reza
    Galsky, Matthew D.
    Bhardwaj, Nina
    Horowitz, Amir
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 53 - 53
  • [7] NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
    Salome, Berengere
    Sfakianos, John P.
    Ranti, Daniel
    Daza, Jorge
    Bieber, Christine
    Charap, Andrew
    Hammer, Christian
    Banchereau, Romain
    Farkas, Adam M.
    Ruan, Dan Fu
    Izadmehr, Sudeh
    Geanon, Daniel
    Kelly, Geoffrey
    Real, Ronaldo M. de
    Lee, Brian
    Beaumont, Kristin G.
    Shroff, Sanjana
    Wang, Yuanshuo A.
    Wang, Ying-chih
    Thin, Tin Htwe
    Garcia-Barros, Monica
    Hegewisch-Solloa, Everardo
    Mace, Emily M.
    Wang, Li
    O'Donnell, Timothy
    Chowell, Diego
    Fernandez-Rodriguez, Ruben
    Skobe, Mihaela
    Taylor, Nicole
    Kim-Schulze, Seunghee
    Sebra, Robert P.
    Palmer, Doug
    Clancy-Thompson, Eleanor
    Hammond, Scott
    Kamphorst, Alice O.
    Malmberg, Karl-Johan
    Marcenaro, Emanuela
    Romero, Pedro
    Brody, Rachel
    Viard, Mathias
    Yuki, Yuko
    Martin, Maureen
    Carrington, Mary
    Mehrazin, Reza
    Wiklund, Peter
    Mellman, Ira
    Mariathasan, Sanjeev
    Zhu, Jun
    Galsky, Matthew D.
    Bhardwaj, Nina
    [J]. CANCER CELL, 2022, 40 (09) : 1027 - +
  • [8] Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A
    Ayass, Mohamad Ammar
    Tripathi, Trivendra
    Griko, Natalya
    Okyay, Tutku
    Ramankutty Nair, Ramya
    Zhang, Jin
    Zhu, Kevin
    Melendez, Kristen
    Pashkov, Victor
    Abi-Mosleh, Lina
    [J]. CANCERS, 2024, 16 (05)
  • [9] NKG2A AND HLA-E DEFINE A NOVEL ALTERNATIVE IMMUNE CHECKPOINT AXIS IN BLADDER CANCER
    Salome, Berengere
    Sfakianos, John
    Charap, Andrew
    Farkas, Adam
    Geanon, Daniel
    Kelly, Geoffrey
    de Real, Ronaldo
    Lee, Brian
    Beaumont, Kristin
    Shroff, Sanjana
    Wang, Ying-Chih
    Wang, Yuan-Shuo
    Wang, Li
    Sebra, Robert
    Kamphorst, Alice
    Malmberg, Karl-Johan
    Marcenaro, Emanuela
    Romero, Pedro
    Brody, Rachel
    Yuki, Yuko
    Martin, Maureen
    Carrington, Mary
    Mehrazin, Reza
    Wiklund, Peter
    Zhu, Jun
    Galsky, Matthew
    Bhardwaj, Nina
    Horowitz, Amir
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A338 - A338
  • [10] NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer
    Salome, Berengere
    Sfakianos, John P.
    Daza, Jorge
    Charap, Andrew
    Farkas, Adam M.
    Geanon, Daniel
    Kelly, Geoffrey
    De Real, Ronaldo M.
    Lee, Brian
    Beaumont, Kristin G.
    Shroff, Sanjana
    Wang, Ying-Chin
    Wang, Yuan-Shuo A.
    Wang, Li
    Sebra, Robert P.
    Kamphorst, Alice O.
    Malmberg, Karl J.
    Marcenaro, Emanuela
    Romero, Pedro
    Brody, Rachel
    Yuki, Yuko
    Martin, Maureen
    Carrington, Mary
    Mehrazin, Reza
    Wiklund, Peter
    Zhu, Jun
    Galsky, Matthew D.
    Bhardwaj, Nina
    Horowitz, Amir
    [J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
12345